KOMBINACIJA INHIBITORA HMG-COA REDUKTAZE ROSUVASTATINA SA INHIBITOROM FOSFODIESTERAZE 4,KAO ŠTO JE ROFLUMILAST, ROFLUMILAST-N-OKSID ZA LIJEČENJE INFLAMATORNIH PLUĆNIH OBOLJENJA
WOLLIN, Stefan-Lutz,MARX, Degenhard,WOHLSEN, Andrea,BRAUN, Clemens
申请号：
MEP914
公开号：
ME01648B
申请日:
2007.07.03
申请国别(地区):
ME
年份:
2014
代理人:
摘要：
The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof.
